

Spectral Medical

Healthcare

17 August 2026

Approaching the finish line

Spectral, in June, submitted its pre-market approval (PMA) application to the US Food and Drug Administration (FDA) for PMX, its proprietary endotoxin removal therapy for patients with endotoxic septic shock (ESS). The product is supported by positive data from the Phase III Tigris follow-on trial. An FDA regulatory decision, projected in H227, would propel the company towards commercialisation of a differentiated treatment in an area of exceptionally high medical need where mortality rates approach c 50%.

PMX targets endotoxins in septic shock patients

Sepsis is a leading cause of hospitalisation deaths worldwide, with [over 350,000 annual deaths in the US alone](#). Septic shock is a particularly severe form of the condition, affecting c 10–20% of hospitalised sepsis patients but accounting for nearly half of all sepsis deaths. PMX is a single-use therapeutic hemoperfusion device designed to remove endotoxins from the bloodstream, which can contribute to sepsis/septic shock. Treatment is guided by Spectral's FDA cleared endotoxin activity assay (EAA) that tests for endotoxin in blood. Septic shock patients with EAA levels between 0.60 and 0.90 represent the potential treatment base for PMX; [at least 30% of septic shock patients](#) are estimated to have EAA levels above 0.60, resulting in a target market of [c 150,000 US patients](#) annually, or up to US\$2.1bn (assumed total PMX treatment cost of US\$15k/patient).

Improved mortality rates confirmed in Tigris

Positive top-line [primary efficacy data in Q325](#) from Spectral's randomised US Phase III [Tigris study](#) (n=157) showed that PMX plus standard of care (SoC) in patients with ESS provided a pooled absolute risk reduction of 8.3% (relative risk reduction of 18%) in 28-day mortality, exceeding the prespecified primary endpoint. Results were also published in [The Lancet](#) and, in June, Spectral reported [12-month survival data](#) from 100% of patients, confirming a continued durability of benefit, with 12-month mortality of 52.8% in the PMX arm versus 66.7% in patients receiving SoC alone, representing an absolute risk reduction of 13.9%.

Valuation: Regulatory catalysts could unlock upside

Spectral's EV of c C\$430m reflects the potential for PMX to provide a differentiated and decisive endotoxin treatment to improve ESS outcomes. Regulatory catalysts, including potential US market approval within the next 12–18 months, could significantly de-risk the development trajectory and trigger a re-rating. Commercial partner Vantive (formerly Baxter's renal division, with c \$4.5bn revenue) holds strong market positions in the renal and acute care settings.


Consensus estimates

Year end	Total revenues (C\$m)	EBITDA (C\$m)	PBT (C\$m)	EPS (C\$)	P/E (x)	EV/EBITDA (x)
12/24	2.3	(10.1)	(15.4)	(0.05)	N/A	N/A
12/25	2.4	(9.4)	(47.7)	(0.16)	N/A	N/A
12/26e	7.3	(9.6)	NA	NA		N/A
12/27e	8.8	(1.3)	NA	NA		N/A

Source: LSEG Data & Analytics

Price **C\$1.38**
Market cap **C\$405m**

Share price performance



Share details

Code	EDT
Listing	TSXV
Shares in issue	293.6m
Net cash/(debt) at 30 June 2026	C\$(23.6)m

Business description

Spectral Medical is advancing Toraymyxin (PMX) for the treatment of patients with endotoxic septic shock. PMX is approved in Japan and Europe, and more than 360k units have been sold worldwide.

Bull points

- Breakthrough Device Designation granted by FDA for PMX for the treatment of ESS.
- Statistically significant positive Phase III Tigris trial results show reduction in ESS mortality vs standard of care across several time periods.
- Commercial strategy largely de-risked through commercial agreement with Vantive.

Bear points

- Regulatory risk remains as path to profitability depends on FDA PMA decision (expected H227).
- Additional fund-raising likely required with c C\$24m in debt outstanding at 30 June and given limited near-term revenue sources.
- Potential competition from competing hemoabsorption devices (eg Baxter's oXiris and CytoSorbents' CytoSorb).

Analysts

Pooya Hemami, OD MBA, CFA	+44 (0)20 3077 5700
Jyoti Prakash, CFA	+44 (0)20 3077 5700

healthcare@edisongroup.com
[Edison profile page](#)

EDISON QUICKVIEWS ARE NORMALLY ONE-OFF PUBLICATIONS WITH NO COMMITMENT TO WRITING ANY FOLLOW UP. QUICKVIEW NOTES USE CONSENSUS EARNINGS ESTIMATES.

General disclaimer and copyright

This report has been prepared and issued by Edison. Edison Investment Research standard fees are £60,000 pa for the production and broad dissemination of a detailed note (Outlook) following by regular (typically quarterly) update notes. Fees are paid upfront in cash without recourse. Edison may seek additional fees for the provision of roadshows and related IR services for the client but does not get remunerated for any investment banking services. We never take payment in stock, options or warrants for any of our services.

Accuracy of content: All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report and have not sought for this information to be independently verified. Opinions contained in this report represent those of the research department of Edison at the time of publication. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations.

Exclusion of Liability: To the fullest extent allowed by law, Edison shall not be liable for any direct, indirect or consequential losses, loss of profits, damages, costs or expenses incurred or suffered by you arising out of or in connection with the access to, use of or reliance on any information contained on this note.

No personalised advice: The information that we provide should not be construed in any manner whatsoever as, personalised advice. Also, the information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The securities described in the report may not be eligible for sale in all jurisdictions or to certain categories of investors.

Investment in securities mentioned: Edison has a restrictive policy relating to personal dealing and conflicts of interest. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report, subject to Edison's policies on personal dealing and conflicts of interest.

Copyright 2026 Edison Investment Research Limited (Edison).

Australia

Edison Investment Research Pty Ltd (Edison AU) is the Australian subsidiary of Edison. Edison AU is a Corporate Authorised Representative (1252501) of Crown Wealth Group Pty Ltd who holds an Australian Financial Services Licence (Number: 494274). This research is issued in Australia by Edison AU and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. Any advice given by Edison AU is general advice only and does not take into account your personal circumstances, needs or objectives. You should, before acting on this advice, consider the appropriateness of the advice, having regard to your objectives, financial situation and needs. If our advice relates to the acquisition, or possible acquisition, of a particular financial product you should read any relevant Product Disclosure Statement or like instrument.

New Zealand

The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (i.e. without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision.

United Kingdom

This document is prepared and provided by Edison for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.

This Communication is being distributed in the United Kingdom and is directed only at (i) persons having professional experience in matters relating to investments, i.e. investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "FPO") (ii) high net-worth companies, unincorporated associations or other bodies within the meaning of Article 49 of the FPO and (iii) persons to whom it is otherwise lawful to distribute it. The investment or investment activity to which this document relates is available only to such persons. It is not intended that this document be distributed or passed on, directly or indirectly, to any other class of persons and in any event and under no circumstances should persons of any other description rely on or act upon the contents of this document.

This Communication is being supplied to you solely for your information and may not be reproduced by, further distributed to or published in whole or in part by, any other person.

United States

Edison relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. This report is a bona fide publication of general and regular circulation offering impersonal investment-related advice, not tailored to a specific investment portfolio or the needs of current and/or prospective subscribers. As such, Edison does not offer or provide personal advice and the research provided is for informational purposes only. No mention of a particular security in this report constitutes a recommendation to buy, sell or hold that or any security, or that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person.